AutekBio
Contract research and manufacturing services for biopharmaceutical and biotech companies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$1.0m | Series B | ||
| Total Funding | 000k | ||
Related Content
AutekBio, Inc. operates as a biopharmaceutical contract development and manufacturing organization (CDMO), strategically positioned with headquarters in the Bay Area, California, and primary manufacturing operations in Beijing, China. Founded in 2006, the company focuses exclusively on providing services for the biopharmaceutical industry, without developing its own internal products. This service-only business model allows AutekBio to function as a dedicated partner for companies ranging from small biotechs to large pharmaceutical corporations.
The company's core business revolves around its "from DNA to NDA" (New Drug Application) service platform, which offers an integrated solution for developing and manufacturing therapeutic proteins and antibodies. AutekBio leverages proprietary technologies for mammalian cell culture to produce biologics. Its services cover the entire biomanufacturing lifecycle, from preclinical and clinical stages to commercial-scale production. Revenue is generated by providing these contract research and manufacturing services to a global clientele of biopharmaceutical companies.
A significant milestone in the company's history occurred in March 2010, when AutekBio announced a joint investment of over $100 million to construct a large-scale R&D and manufacturing center in southern Beijing. This venture was backed by CEO Julius Li and a consortium of investors including SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, the venture capital arm of the Beijing Municipal Government. The facility was designed to meet cGMP standards for both the US FDA and EU EMA, enabling it to serve global biopharmaceutical needs. This expansion was a key part of AutekBio's strategy to provide high-quality, cost-efficient manufacturing solutions and act as a gateway to the Chinese market.
Keywords: CDMO, biopharmaceutical manufacturing, contract development, therapeutic proteins, antibody production, mammalian cell culture, from DNA to NDA, biologics, cGMP facility, clinical manufacturing, commercial manufacturing, bioprocess development, cell line development, Julius Li, Beijing E-Town, SUMA Ventures, China biologics, US-China biotech, protein-based medicines, contract research organization